Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$66.8MCash on Hand
18.9mo Cash Runway
Follow TNYA by emailGet an email when TNYA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about TNYA, unsubscribe in one click. Privacy
📣 What TNYA Says Is Next
second half of 2027 · “The company intends to initiate at least one company-sponsored Phase 2 clinical trial in the second half of 2027.”
Company press release, Nov 4, 2026 · SEC filing
by year end · “The company plans to provide an update on the feedback received from its discussions, along with the additional TN-401 data, by year end.”
Company press release, Nov 4, 2026 · SEC filing
by year end · “Tenaya expects to report additional interim data from the RIDGE-1 clinical trial by year end, including one-year data for Cohort 2 and durability data for Cohort 1.”
Company press release, Nov 4, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 4, 2026 ·
Earnings Reported Q3 2026 net loss of $18.9M ($0.08/share) versus $20.3M a year earlier, with $66.8M cash funding operations into Q4 2027. Received FDA RMAT designation for TN-401; year-end data updates planned for TN-201 and TN-401. Form 8-K · SEC filing · Press release
Nov 4, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Oct 23, 2026 ·
Shareholder vote Tenaya Therapeutics is asking stockholders to approve a reverse stock split at a ratio between 1-for-10 and 1-for-25, with the exact ratio to be set by the board. The special meeting is set for December 9, 2026, and the board may still choose not to proceed. Form DEF 14A · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Aug 2027 · Phase 1/2 · Recruiting · Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM Registry primary completion date, not a results date
Jun 2028 · N/A · Active Trial · Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy Registry primary completion date, not a results date
Mar 2030 · N/A · Recruiting · Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated… Registry primary completion date, not a results date
💰 Cash Runway & Dilution Risk
TNYA holds $66.8M in cash and short-term investments (as of Sep 30, 2026) and burns about $10.6M/quarter from operations,
an estimated runway of 18.9 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:47 · Elevated
Cash runway 19 months +8
ATM program on file since Mar 2025 +15
Shelf registration (S-3, Mar 2025) +10
Share count +37% in a year +14
Recent financing filings on SEC EDGAR:
Dec 12, 2025 · Underwritten offering, $60M · 424B5
Share count 227,928,240 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full TNYA picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TNYA and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.